logo
Plus   Neg
Share
Email

Sartorius Q1 Adj. Profit Improves; Reaffirms 2012 Outlook - Quick Facts

Sartorius (SDMHF.PK) said its first-quarter adjusted consolidated net profit after non-controlling interest, excluding non-cash amortization and valuation of hedging instruments, surged to 14.2 million euros or 0.83 euros per share from 10.6 million euros or 0.62 euros per share in the same quarter a year earlier.

Sales revenue for the three-month period climbed to 208.1 million euros from 172.1 million euros in the previous year.

Order intake for the quarter was 220 million euros versus 193.5 million euros a year ago.

Going ahead, based on the company's first-quarter performance, management confirms its guidance for sales and earnings growth for the current fiscal year. The company thus anticipates that full-year sales will grow by about 10% in constant currencies. Around five percentage points of this gain are forecast to be generated by the initial consolidation of the Biohit liquid handling business. Besides, management continues to project that operating EBITA will likewise increase by around 10%.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT